Tuesday, 22 Oct 2019

You are here

Management of Digital Ulcers in Scleroderma

Currently there are no FDA-approved medications for the treatment of digital ulcerations in the United States.  Digital ulcers are a common, unfortunate and difficult to manage consequence of the vascular obliteration and fibrosis that accompanies systemic sclerosis.

Drs. Abraham and Steen from the Georgetown University Hospital review the clinical evidence for managing Raynaud's phenomenon and digital ulcers. While Raynaud's is seen in nearly all SS patients, digital ulcers are seen in up to 30%, and its incidence may be decreasing. Aside from avoidance of cold and smoking, medications that promote vasoconstriction should be avoided (including beta blockers, migraine medicines sumatriptan and ergotamine, birth control pills and amphetamines). This review details the benefits and use of calcium channel blockers, phosphodiesterase inhibitors, sildenafil, vardenafil, tadalafil, prostacyclin analogues, bosentan, nitrates, N-acetylcysteine, ACE inhibitors, ASA, wound care, sympathectomy, botulinum toxin, autologous fat grafting and surgery.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.